ASTELLAS PHARMA KOREA, INC.
๐ฐ๐ทSouth Korea
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Recruiting
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT06902545
- Locations
- ๐ฐ๐ท
KR82004, Seoul, Korea, Republic of
๐ฐ๐ทKR82001, Seoul, Korea, Republic of
Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
Completed
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT06452212
- Locations
- ๐ฐ๐ท
KR82001, Seoul, Korea, Republic of
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Recruiting
- Conditions
- Urothelial Cancer
- Interventions
- Drug: Enfortumab Vedotin
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT06011954
- Locations
- ๐ฐ๐ท
Site KR82001, Goyang-si, Gyeonggi-do, Korea, Republic of
๐ฐ๐ทSite KR82012, Suwon-si, Gyeonggi-do, Korea, Republic of
๐ฐ๐ทSite KR82008, Suwon-si, Gyeonggi-do, Korea, Republic of
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
Completed
- Conditions
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT04691648
- Locations
- ๐ฐ๐ท
Site KR82013, Wonju-si, Gangwon-do, Korea, Republic of
๐ฐ๐ทSite KR82006, Goyang-si, Gyeonggi-do, Korea, Republic of
๐ฐ๐ทSite KR82003, Jeollanam-do, Hwasun-gun, Korea, Republic of
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03737708
- Locations
- ๐ฐ๐ท
Site KR82003, Daegu, Korea, Republic of
๐ฐ๐ทSite KR82007, Daegu, Korea, Republic of
๐ฐ๐ทSite KR82006, Daejeon, Korea, Republic of
Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation
Completed
- Conditions
- Kidney Transplantation
- Interventions
- Behavioral: Qualitative interviews with participants
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03623217
- Locations
- ๐ฐ๐ท
Site 1, Seoul, Korea, Republic of
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
Phase 4
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03118713
- Locations
- ๐ฐ๐ท
Site 13, Busan, Korea, Republic of
๐ฐ๐ทSite 02, Deagu, Korea, Republic of
๐ฐ๐ทSite 11, Guri-si, Korea, Republic of
A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02963103
- Locations
- ๐ฐ๐ท
KR00001, Seoul, Korea, Republic of
Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor
Phase 4
Completed
- Conditions
- Graft Versus Host Disease
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02660684
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT02452632
- Locations
- ๐ฐ๐ท
Site KR00002, Busan, Korea, Republic of
๐ฐ๐ทSite KR00003, Busan, Korea, Republic of
๐ฐ๐ทSite KR00007, Daegu, Korea, Republic of